…le, the MS Progression Discussion Tool (MSProDiscuss, https://msprodiscuss.com/) was developed by clinicians in Canada, the U.S. and Germany to help evaluate early signs of progression and to facilitate patient discussions about SPMS. In the validation study, the web-based tool took about two minutes to complete (Ziemssen et al. Med Internet Res 2020; 22:e16932). Included were questions on disease activity, symptoms (intermittent/improving/stable/…

…ts A booster is generally advised for all patients A booster is strongly recommended for at-risk patients (older age, disabilities, comorbidities) and those on a high-efficacy DMT; boosters advised for all others Boosters are at the discretion of the patient Boosters are generally not discussed Are you advising DMT-treated patients on the timing of their boosters? Yes, the same timing as recommended by the Canadian Network for the initial two vacc…

…-reported declines in QoL and activities of daily living or other changes (complete the survey to view the results at https://neuro-sens.com/is-all-ms-progressive/). Such a broader perspective may help to identify the onset of progression earlier and more adequately meet the needs and concerns of patients. The Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) announced this year should provide additional insights on how…